Literature DB >> 15969315

[Is fibrinogen a predictor or a marker of the risk of cardiovascular events?].

Ludovic Drouet1, Claire Bal dit Sollier.   

Abstract

Most cardiovascular events result from a thrombotic complication of an atherosclerotic lesion. Inflammation plays a central role in both the pathogenesis of atherosclerosis and the progression of its complications (especially plaque rupture). Fibrinogen, on the one hand a marker of inflammation and on the other a major determinant in thrombosis and haemorrheology, plays a central role in atherosclerosis and its thrombotic complications. The clinical data are in agreement with epidemiological data, and show that increased plasma fibrinogen levels (compared with values in paired controls) are predictive of the risk of cardiovascular events - both primary cardiovascular events in the general population and recurrence in patients. Determining the plasma fibrinogen level in terms of genetic predisposition and environmental factors provides a good example of the interrelationship between genes and the environment. It must be recognised that a minimal increase in the fibrinogen level (within the plasma reference values) is an indicator of a significantly increased risk. This shows why epidemiological data are not useful for determining cardiovascular risk in individual patients in daily clinical practice (with the exception of the very high levels that are infrequently observed).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969315     DOI: 10.2515/therapie:2005017

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  4 in total

1.  The Effect of Subclinical Hypothyroidism on Coagulation and fibrinolysis: A Systematic Review and Meta-Analysis.

Authors:  Qinglei Xu; Yulong Wang; Xue Shen; Yunfeng Zhang; Qingyun Fan; Wei Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

2.  Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.

Authors:  Amra Macić-Dzanković; Fuad Dzanković; Belma Pojskić; Zelija Velija-Asimi
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

3.  Risk factors of embolism for the cardiac myxoma patients: a systematic review and metanalysis.

Authors:  Yanna Liu; Jiwei Wang; Liangyun Guo; Luyi Ping
Journal:  BMC Cardiovasc Disord       Date:  2020-07-25       Impact factor: 2.298

4.  The Correlation Between FGB Promoter Polymorphism and Clotting Function in Patients With Idiopathic Lower Extremity Deep Venous Thrombosis.

Authors:  Shengbin Han; Bin Yang; Yaoyu Feng; Lingfeng Zhao; Qun Feng; Hongxi Guan; Donghui Song; Fang Yin; Li Zhuang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.